Tezze C, Romanello V, Sandri M (2019) FGF21 as modulator of metabolism in health and disease. Front Physiol 10:419. https://doi.org/10.3389/fphys.2019.00419

Article  PubMed  PubMed Central  Google Scholar 

Lewis JE, Ebling FJP, Samms RJ, Tsintzas K (2019) Going back to the biology of FGF21: new insights. Trends Endocrinol Metab 30:491–504. https://doi.org/10.1016/j.tem.2019.05.007

Article  CAS  PubMed  Google Scholar 

Staiger H, Keuper M, Berti L, Hrabe de Angelis M, Haring HU (2017) Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev 38:468–488. https://doi.org/10.1210/er.2017-00016

Article  PubMed  Google Scholar 

Kaur N, Gare SR, Shen J, Raja R, Fonseka O, Liu W (2022) Multi-organ FGF21-FGFR1 signaling in metabolic health and disease. Front Cardiovasc Med 9:962561. https://doi.org/10.3389/fcvm.2022.962561

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203–206. https://doi.org/10.1016/S0167-4781(00)00067-1

Article  CAS  PubMed  Google Scholar 

Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5(6):426–437. https://doi.org/10.1016/j.cmet.2007.05.002

Article  CAS  PubMed  Google Scholar 

Liu C, Schönke M, Spoorenberg B, Lambooij JM, van der Zande HJP, Zhou E, Tushuizen ME, Andreasson AC, Park A, Oldham S, Uhrbom M, Ahlstedt I, Ikeda Y, Wallenius K, Peng XR, Guigas B, Boon MR, Wang Y, Rensen PCN (2023) FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife 12:e83075. https://doi.org/10.7554/eLife.83075

Article  PubMed  PubMed Central  Google Scholar 

Gimeno RE, Moller DE (2014) FGF21-based pharmacotherapy–potential utility for metabolic disorders. Trends Endocrinol Metab 25(6):303–311. https://doi.org/10.1016/j.tem.2014.03.001

Article  CAS  PubMed  Google Scholar 

Dostálová I, Haluzíková D, Haluzík M (2009) Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 58(1):1–7. https://doi.org/10.33549/physiolres.931610

Article  PubMed  Google Scholar 

Tillman EJ, Rolph T (2020) FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne) 11:601290. https://doi.org/10.3389/fendo.2020.601290

Article  PubMed  Google Scholar 

Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P (2022) The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol 13:1089214. https://doi.org/10.3389/fphar.2022.1089214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018–6027. https://doi.org/10.1210/en.2008-0816

Article  CAS  PubMed  Google Scholar 

Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, Weiszmann J, Stevens J, Chen JS, Nuanmanee N, Gupte J, Komorowski R, Sekirov L, Hager T, Arora T, Ge H, Baribault H, Wang F, Sheng J, Karow M, Wang M, Luo Y, McKeehan W, Wang Z, Véniant MM, Li Y (2012) Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 4(162):162ra153. https://doi.org/10.1126/scitranslmed.3004690

Article  CAS  PubMed  Google Scholar 

Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N (2013) Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther 346(2):270–280. https://doi.org/10.1124/jpet.113.204420

Article  CAS  PubMed  Google Scholar 

Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, Li S, Koester A, Ford AM, Coskun T, Dunbar JD, Cheng CC, Frye CC, Bumol TF, Moller DE (2013) Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8(3):e58575. https://doi.org/10.1371/journal.pone.0058575

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1):250–259. https://doi.org/10.2337/db08-0392

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weng Y, Chabot JR, Bernardo B, Yan Q, Zhu Y, Brenner MB, Vage C, Logan A, Calle R, Talukdar S (2015) Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS ONE 10(3):e0119104. https://doi.org/10.1371/journal.pone.0119104

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nielsen MH, Gillum MP, Vrang N, Jelsing J, Hansen HH, Feigh M, Oró D (2023) Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 324(5):G378–G388. https://doi.org/10.1152/ajpgi.00157.2022

Article  CAS  PubMed  Google Scholar 

Tyynismaa H, Carroll CJ, Raimundo N, Ahola-Erkkilä S, Wenz T, Ruhanen H, Guse K, Hemminki A, Peltola-Mjøsund KE, Tulkki V, Oresic M, Moraes CT, Pietiläinen K, Hovatta I, Suomalainen A (2010) Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 19(20):3948–3958. https://doi.org/10.1093/hmg/ddq310

Article  CAS  PubMed  Google Scholar 

Vandanmagsar B, Warfel JD, Wicks SE, Ghosh S, Salbaum JM, Burk D, Dubuisson OS, Mendoza TM, Zhang J, Noland RC, Mynatt RL (2016) Impaired mitochondrial fat oxidation induces FGF21 in muscle. Cell Rep 15(8):1686–1699. https://doi.org/10.1016/j.celrep.2016.04.057

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosales-Soto G, Diaz-Vegas A, Casas M, Contreras-Ferrat A, Jaimovich E (2020) Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol 65(3):85–95. https://doi.org/10.1530/JME-19-0210

Article  CAS  Google Scholar 

Keipert S, Ost M, Johann K, Imber F, Jastroch M, van Schothorst EM, Keijer J, Klaus S (2014) Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. Am J Physiol Endocrinol Metab 306(5):E469–E482. https://doi.org/10.1152/ajpendo.00330.2013

Article  CAS  PubMed  Google Scholar 

Fisher FM, Maratos-Flier E (2016) Understanding the physiology of FGF21. Annu Rev Physiol 78:223–241. https://doi.org/10.1146/annurev-physiol-021115-105339

Article  CAS  PubMed  Google Scholar 

Ribas F, Villarroya J, Hondares E, Giralt M, Villarroya F (2014) FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling. Biochem J 463(2):191–199. https://doi.org/10.1042/BJ20140403

Article  CAS  PubMed  Google Scholar 

Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T, Nielsen S, Pedersen BK (2009) Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58(12):2797–2801. https://doi.org/10.2337/db09-0713

Article  CAS  PubMed  PubMed Central  Google Scholar 

Domouzoglou EM, Vlahos AP, Cholevas VK, Papafaklis MI, Chaliasos N, Siomou E, Michalis LK, Tsatsoulis A, Naka KK (2021) Association of fibroblast growth factor 21 with metabolic syndrome and endothelial function in children: a prospective cross-sectional study on novel biomarkers. Ann Pediatr Endocrinol Metab 26(4):242–251. https://doi.org/10.6065/apem.2040258.129

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Li S, Qiu Y, Zhou M, Chen M, Hu Y, Hong S, Jiang L, Guo Y (2022) Circulating FGF21 and GDF15 as biomarkers for screening, diagnosis, and severity assessment of primary mitochondrial disorders in children. Front Pediatr 10:851534. https://doi.org/10.3389/fped.2022.851534

Article  PubMed  PubMed Central  Google Scholar 

Tanajak P, Pongkan W, Chattipakorn SC, Chattipakorn N (2018) Increased plasma FGF21 level as an early biomarker for insulin resistance and metabolic disturbance in obese insulin-resistant rats. Diabetes Vasc Dis Res 15:263–269. https://doi.org/10.1177/1479164118757152

Article  CAS  Google Scholar 

Owen BM, Mangelsdorf DJ, Kliewer SA (2015) Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab 26(1):22–29. https://doi.org/10.1016/j.tem.2014.10.002

Article  CAS  PubMed  Google Scholar 

Geng L, Lam KSL, Xu A (2020) The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 16:654–667. https://doi.org/10.1038/s41574-020-0386-0

Article  CAS  PubMed  Google Scholar 

Jung YE, Lee KW, Cho JH, Bae DW, Jeong BG, Jung YJ, Park SB, An YJ, Kim K, Lee GS, Kang LW, Moon JH, Lee JH, Kim EK, Yim HS, Cha SS (2023) Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency. Sci Rep 13(1):1005.